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Abstract
Primary glioblastomas are subdivided into several molecular subtypes. There is an ongoing debate over the cell of origin for
these tumor types where some suggest a progenitor while others argue for a stem cell origin. Even within the same molecular
subgroup, and using lineage tracing in mouse models, different groups have reached different conclusions. We addressed this
problem from a combined mathematical modeling and experimental standpoint. We designed a novel mathematical
framework to identify the most likely cells of origin of two glioma subtypes. Our mathematical model of the unperturbed in
vivo system predicts thatif a genetic event contributing to tumor initiation imparts symmetric self-renewing cell division (such
as PDGF overexpression), then the cell of origin is a transit amplifier. Otherwise, the initiating mutations arise in stem cells. The
mathematical framework was validated with the RCAS/tv-a system of somatic gene transfer in mice. We demonstrated that
PDGF-induced gliomas can be derived from GFAP-expressing cells of the subventricular zone or the cortex (reactive
astrocytes), thus validating the predictions of our mathematical model. This interdisciplinary approach allowed us to
determine the likelihood that individual cell types serve as the cells of origin of gliomas in an unperturbed system.
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Introduction
Glioblastomas (GBMs) are the most common primary brain
tumors [1]. Over the years, our understanding of GBM biology
has greatly improved, but the cell of origin for these tumors is still
debated [2]. Some studies have demonstrated that neural stem
cells (NSCs), located in the subventricular zone (SVZ), are a
possible target for transformation [2]. NSCs in the SVZ and in the
subgranular zone (SGZ) are capable of self-renewal and give rise to
the three cell types in the central nervous system [3]. However,
several studies suggested that extracellular signals can affect glial
cell specification and may convert specified precursors into
multipotential stem cells [4]. The cerebral cortex contains many
cell types including astrocytes and oligodendroglial progenitor cells
(OPCs) that have been reported to behave stem-like under certain
culture or pathologic conditions [4,5]. In fact, several of the major
genetic alterations associated with gliomas confer some of the
properties of stem cells [6].
Genomic and expression analyses of GBMs imply that they are
not a single tumor type, but fall into several distinct subtypes;
similarly, the cell of origin for these glioma types may well not be
the same. Two studies have used correlative expression profiling to
subdivide the tumors into groups based on similarities to known
cell types named either proneural, proliferative, and mesenchymal
[7], or proneural, neural, classical, and mesenchymal [8]. In
addition, a combination of proteomic and genomic analyses have
been used to subdivide these tumors into three subclasses based on
signal transduction pathway activation and genetic alterations: the
NF1, EGFR and PDGFR classes [9].
Mutations in the NF1 gene have long been known to predispose
to glioma formation, as these tumors are part of the tumor
spectrum of the NF syndrome [10]. Recently, The Cancer
Genome Atlas (TCGA) consortium showed that a surprisingly
large number of sporadic GBMs have NF1 mutations and define a
subgroup of GBM [9,11]. Genetic modeling of this GBM subtype
in mice achieved by deleting NF1, TP53 and/or PTEN in nestin-
expressing cells (NSCs/PC) and GFAP-expressing cells (NSCs and
white matter astrocytes) results in tumors histologically identical to
human gliomas [12]. Moreover, stereotactic injection of cre-
expressing adenovirus further demonstrated that these tumors
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but not in more differentiated cells residing in the cortex [12]. In
apparent contrast to these findings, recent usage of Mosaic
Analysis with Double Markers (MADM) identified oligodendro-
cyte precursor cells (OPCs) to be the cell of origin in gliomas
induced by concurrent mutation of TP53 and NF1 [13]. Loss of
NF1 was shown to transiently promote self-renewal [14], but
acquisition of long-term self-renewal by NF1 loss has not been
reported.
A well-documented alteration in GBM is amplification and
activating mutation (EGFRVIII)o fEGFR. TCGA analysis of
gliomas shows this mutation to be frequently associated with
PTEN loss and to be the signature lesion of the EGFR subset of
GBMs [9,11]. Modeling of this subtype of GBM has been
achieved in adult mice by adenoviral Cre delivery to the striatum
to activate expression of EGFR (both WT and VIII) with
simultaneous inactivation of PTEN and INK4A/ARF [15]. As
adenoviral vectors are not cell type-specific, the cell of origin for
these cre-induced tumors is not well-defined.
The third major signaling subset of gliomas is characterized by
dysregulated PDGFR activity, which in some cases is due to
amplification and rearrangement of the PDGFR-a gene locus, and
in others to overexpression of the PDGF ligand [9]. The PDGFR
subclass accounts for 25-30% of GBMs and overlaps with the
proneural transcriptomal class of GBMs. The PDGF subset of
gliomas has been modeled effectively using either MLV-based
retroviral gene transfer or RCAS-mediated gene transfer in
rodents [16,17,18]. These tumors can arise in neonatal or adult
mice from either GFAP- or nestin-expressing cells, representing
differentiated and self-renewing cells, respectively. Stereotactic
injection of RCAS vector-mediated PDGF-induced gliomas from
nestin-expressing cells shows similar incidence and latency when
injected in the SVZ and the cortex of adult mice [18]. Although
nestin is induced in the cortex by injury, the fact that nestin is also
a stem cell/progenitor marker clouds the interpretation of these
results. However, OPCs can also serve as the cells of origin for
these gliomas. RCAS-PDGF injection into the cortex of Ctv-a
(29,39-cyclic nucleotide 39-phosphodiesterase (Cnp) cnp-tv-a) mice
results in efficient glioma formation [19]. Recent studies of a
mouse model of glioma driven by v-ErbB further validated that
OPCs rather than NSCs serve as the cell of origin for murine
oligodendroglioma [20].
The identity of the cell of origin for cancer has recently received
much attention [21]. Different cells of origin could explain
phenotypic differences between tumors associated with the same
characteristic molecular abnormalities [22,23,24]. Furthermore,
different cells of origin may require different combinations of
oncogenic mutations that could affect the biology and/or
therapeutic response of the tumors. It is therefore of significant
interest to identify the cell of origin of human tumors. In this
context, we define the cell of origin to be the first cell in which all
genetic alterations necessary to initiate tumorigenesis are accu-
mulated. This cell may be distinct from ‘‘tumor-propagating’’ cells,
which maintain the tumor bulk [21].
In this paper, we have designed and analyzed a mathematical
framework to identify the most likely cell of origin of glioblastoma.
Given that previous mouse experiments have shown that PDGF
overexpression may drive de-differentiation of glial cells [16], and
recent mouse models have acknowledged the possibility of forcing
a non-self-renewing cell to become the cell of origin [18], we
sought to mathematically determine how likely such a non-stem
cell origin may be. Thus, our model investigates a mechanism
(cellular dedifferentiation induced by factors such as PDGF) by
which such a cell of origin may occur and tests over a wide set of
parameter regimes estimated from the glioma literature (see the
Results section) whether and how often this mechanism is used. We
considered two different subsets of gliomas: those that are driven by
overexpression of PDGF,and thosedriven bylossof NF1. We found
that if a genetic event contributing to tumor initiation imparts
symmetric self-renewing cell division (such as PDGF overexpres-
sion), then the most likely cell of origin is a transit amplifier. If no
such mutation emerges, then the cell of origin is a stem cell. These
mathematical modeling experiments can be used to determine the
likelihood and circumstances under which specific cell types initiate
PDGF- and NF1-induced gliomagenesis. This approach is unlike
mouse modeling experiments, which can only determine the ability
of a certain cell type to initiate glioma development in response to
overexpression ofa gene,suchasinthe PDGF-driven case,orlossof
function of a gene, as in the NF1-driven case, at a particular point in
time. Mouse modeling does not ensure that the set of events that
result in a particular cell of origin actually occurs in vivo. Thus,
mouse modeling approaches cannot address the relative likelihood
of different cell types to serve as the cell of originin the unperturbed,
non-engineered system evolving due to spontaneous mutation. The
key advantage of mathematical modeling is that the evolution of
human tumors can be recapitulated without having to impose the
emergence of mutations at specific times, such as in the mouse
model. This fact makes mathematical modeling uniquely able to
address the identity of the cell of origin in naturally evolving tumors.
However, mouse experiments are useful for validating a subset of
predictions of the mathematical model – for instance, as outlined in
the Results section, the mathematical framework predicts that
gliomas driven by a genetic event which imparts symmetric self-
renewing cell division (such as PDGF) should be able to be induced
in all locations within the brain, while gliomas driven by genetic
events which do not impart such characteristics can only arise from
neural stem cells. To validate these predictions, we used the RCAS/
tv-a system to target PDGF expression to GFAP-expressing cells of
the SVZ, cortex and cerebellum. We found that PDGF expression
in all three locations led to glioma formation. These results are in
marked contrast to one set of experiments performed with the NF1-
driven subclass of gliomas; stereotactic injection of cre recombinase
to remove floxed NF1 and TP53 resulted in glioma formation only
in the SVZ and not in the cortex or cerebellum [12]. This
interdisciplinary approach of mathematical modeling and experi-
mental validation provides a powerful new way of investigating the
cell of origin of human tumors.
Results
Mathematical modeling of gliomagenesis identifies the
most likely targets of transformation for different glioma
subtypes
We designed a mathematical framework of the dynamics of
proliferating cells in the brain, consisting of self-renewing (SR) cells
and their transit-amplifying, non-self-renewing progeny (TA cells)
(see Supporting Information S1 for details of the framework). We
chose to begin with a detailed stochastic simulation in order to
better capture the intricacies of the cell populations of the brain.
Simpler analytic models may represent portions of the system
dynamics [25]; however, they can only provide an approximate
understanding of how the system functions in detail. To accurately
capture the intricacies of the full system, an extended model must
be designed that includes further parameters which may alter the
conclusions of any simpler model [26].
We first modeled the population of SR cells residing in the SVZ.
We considered this population to consist of multiple independent
cell clusters or niches of 1 to 10 cells each [27] and denoted the
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dynamics of one niche within the brain since the total probability
of cancer initiation is given by the probability per niche times the
number of niches, since the niches are independent. Hence, a
consideration of all niches does not alter the most likely cell of
origin of brain cancer. Within a niche, a single SR cell is randomly
chosen to divide during each time step, following a stochastic
process known as the Moran model [28]. According to this model,
one daughter cell of the division replaces the divided cell; the other
daughter cell replaces another cell in the population, which
undergoes apoptosis. During each division, a mutation may occur
in either one of the daughter cells.
SR cells do not produce only other SR cells. With probability a,
the cell division in the current time step is symmetric and follows
the traditional Moran process, while with probability 12a, the SR
division is asymmetric and results in one self-renewing and one
non-self-renewing cell. In the latter case, the SR daughter cell
replaces the divided cell, and the TA daughter cell begins a
differentiation cascade. With each asymmetric SR cell division, all
TA cells in the simulation undergo symmetric divisions, producing
two daughter cells of successively more differentiated status (Fig. 1).
Unmutated TA cells undergo z symmetric cell divisions before
terminally differentiating; at this point, they are no longer
considered in our mathematical model. Thus, in the wild-type
system, there are N SR and 2
z+121 TA cells per niche.
During each SR and TA cell division, genetic alterations
contributing to gliomagenesis may arise. We considered two
subtypes of primary glioblastoma: the subtype driven by NF1 loss
and the subtype driven by PDGF overexpression. For NF1-driven
cancers, we investigated bi-allelic loss of NF1 and a dominant
negative mutation of TP53 as the necessary driver mutations that
must be accumulated in a single cell to initiate tumorigenesis. For
PDGF-driven cancers, the necessary driving alterations are those
leading to PDGF overexpression and bi-allelic loss of INK4A/ARF.
We did not include the accumulation of passenger mutations in
this model since those alterations, by definition, do not influence
the systems dynamics. The rates at which alterations leading to loss
of NF1, INK4A/ARF, and TP53, and overexpression of PDGF
arise per allele per cell division were denoted by mNF1, mARF, mTP53,
and mPDGF respectively. For both glioma subtypes, we assumed that
a single cell that accumulates all required mutations and either
retains or acquires the ability to self-renew is necessary and
sufficient to initiate cancer. The cell of origin was then defined as
the cell in which the last one of the necessary alterations emerges;
this choice was made since the clone carrying the first mutation
may often go extinct or not accumulate the other alterations
necessary for tumor initiation.
We classified genetic alterations into two distinct classes
according to their mutational effects. Mutations in INK4A/ARF,
TP53, and NF1 were considered to result in increased prolifera-
tion. Since bi-allelic loss of INK4A/ARF and dominant negative
TP53 mutations lead to increased proliferative capabilities of cells
[29,30], the relative fitness (i.e. growth rate) of INK4A/ARF
2/2
and TP53
+/2 SR cells as compared to wild type cells are given by
RARF.1 and RTP53.1. Thus, in the SR cell niche, these mutant
cells have a probability proportional to their relative fitness to be
selected for cell division during each time step. Additionally,
INK4A/ARF
2/2 and TP53
+/2 TA cells undergo bARF and bTP53
further cell divisions beyond the normal z divisions, respectively,
before terminal differentiation (Fig. 2A). Since INK4A/ARF is a
potent activator of TP53, the effects of alterations in these genes
are not independent; we considered RARF=RTP53 and
bARF=bTP53, and also assumed that the fitness and additional
divisions of cells carrying alterations in both genes is equal to those
of cells carrying alterations in either gene alone [31]. Loss of NF1
similarly leads to increased proliferative activity of cells if it arises
on the background of either TP53 or INK4A/ARF loss [32]; hence
INK4A/ARF
2/2 NF1
2/2 cells were considered to have relative
fitness RARF 6RNF1,mut and divide a total of z + bARF + bNF1 times.
In contrast, cells mutated in NF1 without any other mutation have
a fitness detriment, RNF1,wt<0.05, and cannot undergo additional
cell divisions beyond the normal z divisions [33].
Figure 1. A mathematical model of the cell of origin of PDGF- and NF1-driven gliomas. Initially, there are N wild-type self-renewing (SR)
cells (blue) and 2
z+121 wild-type transit-amplifying non-self-renewing (TA) cells (purple). At each time step, a SR cell is chosen to divide. With
probability a, the SR cell divides symmetrically and one daughter cell replaces another randomly chosen SR cell. With probability 12a, the SR cell
divides asymmetrically and one daughter cell remains a SR cell while the other daughter cell becomes committed to the TA population (light pink).
This new TA cell divides symmetrically z times to give rise to successively more differentiated cells (progressively darker shades of purple) before
becoming terminally differentiated. This restriction of the stochastic process ensures that the total number of cells is constant over time, and mimics
homeostatic conditions in the healthy brain. In the figure, the darkening purple gradations refer to successively more differentiated cells and serve to
clarify a single time step of the stochastic process. We investigate the dynamics of only one cell cluster since the total probability of cancer initiation is
given by the probability per cluster times the number of clusters; hence, a consideration of all clusters does not alter the identity of the most likely
cell of origin of brain cancer.
doi:10.1371/journal.pone.0024454.g001
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SR cells as well as potential recruitment of other cells, and decreases
the turnover time of cells [17,34]. Hence we modeled the effect of
PDGF overexpression in an SR cell cluster to be instantaneous
expansion of the SR population and increase in the number of cell
divisions per time step, both by a factor of C (Fig. 2B). Furthermore,
PDGF-overexpressing non-self-renewing cells may acquire the
ability to self-renew [16]. The rate of acquisition of self-renewal of
TA cells that overexpress PDGF is given by c – j*cstep, where c
representsthe baserate ofacquisitionofself-renewal,jisthenumber
of differentiating cell divisions the TA cell has undergone, and cstep is
the level of decrease in self-renewal acquisition with differentiation.
We chose to describe this effect through two parameters to
encompass a decreasing probability of regaining self-renewal,
resulting from either an increase in differentiation preventing self-
renewal, or a loss of influence of microenvironmental factors as the
TA cells leave the SVZ. The first TA cell to become self-renewing
exits the TA populationand founds a new niche of CN self-renewing
TA (SRTA) cells (Fig. 2C). We referred to the event in which a
PDGF-overexpressing TA cells acquires self-renewing properties
and leaves the TA population as a ‘gamma event’. The initial
gamma event leads to a new clone of CN SRTA cells, and every
gamma event thereafter causesa TA cell to leavethe TA population
and enter the SRTA pool. These SRTA cells are self-renewing;
however, we did not require that they recapitulate the full SR cell
phenotype. The SRTA population then behaves in the same
manner as the SR cell population, except that no asymmetric
divisions can occur in this simplest version of the model; see
Supporting Information S1 for a discussion of alternative
assumptions and their effects.
We also considered two further non-mutational effects on the
system. SR cells may occasionally produce two TA daughter cells
[35,36,37,38], a process we described by introducing a parameter
l into the system. With probability l, an SR cell division produces
one TA daughter cell and one SR daughter cell (asymmetric
division), while with probability 12l, the SR cell division
produces two TA daughter cells and no SR daughter cells. In
order to maintain homeostasis, an additional symmetric SR cell
division is then induced to replace the lost cell. Additionally, we
considered the possibility of random cell death, where all cells have
a probability d of undergoing apoptosis per time step. In the SR
cell compartment, these deaths are compensated for by an
additional cell division; in the TA cell population, another cell of
the same maturity is chosen to divide again to replace the lost cell.
The two replacement daughter cells are of the same maturity as
the dead and divided cells.
We performed exact computer simulations of this stochastic
process and also derived analytical approximations of the
probabilities of cancer initiation from the different cell types (see
Supporting Information S1 and Figs. S1 and S2). These
approximations are useful for deriving predictions for parameter
regimes for which the direct simulations would be computationally
too expensive (Figs. S3).
To accurately determine the probability that a specific cell type
serves as the cell of origin for PDGF- and NF1-driven gliomas,
estimates of the system parameters are essential. We referred to
investigations into the properties of glial cell lineages to obtain the
most accurate estimates, but tested a range of values consistent
with the literature to ensure the stability and robustness of our
results; for those parameters for which an estimate had not been
determined experimentally, we tested a large range of potential
parameter values (see Supporting Information S1).
Let us now discuss the parameters in detail. The SVZ contains
distinct cell clusters of 1–10 SR cells, each surrounded by
Figure 2. The effects of genetic alterations contributing to
gliomagenesis. A) The acquisition of inactivating mutations in both
alleles of INK4A/ARF, both alleles of NF1, and a dominant negative
mutation in TP53 all result in an increased relative fitness (i.e. growth
rate) of SR and SRTA cells (red) as compared to wild type cells (blue) and
an increased number of divisions TA cells can undergo before terminally
differentiating. INK4A/ARF
2/2 and TP53 dominant negative cells have
relative fitness values of RARF and RTP53, respectively, while NF1
2/2 cells
have differing relative fitness values depending on the other mutations
they harbor. If inactivating mutations in TP53 or INK4A/ARF are present
in the same cell, then NF1
2/2 cells have relative fitness RNF1,mut; if those
mutations are not present, they have relative fitness RNF1,wt. Each
mutation provides an additional bARF, bNF1,o rbTP53 divisions that TA
cells can undergo; hence INK4A/ARF
2/2cells divide z+bARF times instead
of the usual z times. However, the additional divisions due to NF1 loss
only occur if either the TP53 or the INK4A/ARF mutation has already
been accumulated. B) If a cell overexpressing PDGF (red) reaches 100%
frequency in either the SR or SRTA cell population, then clonal
expansion by a factor of C of that population occurs. C) PDGF
overexpression leads to a potential transition to symmetric self-
renewing cell division in TA cells (pink arrow). The rate of acquisition
of self-renewal of a PDGF-overexpressing TA cell which has divided k
times is given by ck=max(c 2kcstep, 0), where c is the rate of the most
undifferentiated TA cell and cstep the factor by which this rate decreases
per TA cell division. The first TA cell to become self-renewing exits the
TA population and founds a new compartment of N self-renewing TA
cells (gray oval). Every TA cell thereafter joins the new population, and,
of the total cells in the compartment, N cells survive each time step.
During each time step thereafter, a symmetric division occurs in this
compartment wherein the offspring of one cell replaces another
randomly chosen cell.
doi:10.1371/journal.pone.0024454.g002
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that the number of SR cells per niche is about N<5. Due to lack of
information about the rates of symmetric division of adult SR cells,
we considered the rate of symmetric cell division of mature SR
cells to be similar to division rates of radial glial cells. In order to
maintain their self-renewing nature, the apical-basal polarity of
these cells must be sustained [39]. Since the apical plasma
membrane of SR cells consists of only 1–2% of the total plasma
membrane, it was proposed [40] and later shown [39] that division
of the apical plasma membrane governs symmetric versus
asymmetric cell divisions. Since 40% of SR cells in the SVZ are
dividing vertically and the remainder are dividing horizontally or
obliquely [41], and roughly 50% of vertically dividing SR cells and
none of the horizontally or obliquely dividing cells split the apical
plasma membrane [39], the rate of symmetric SR cell division is
a<0.2. We also considered the possibility of a symmetric
differentiation event in our model; however, the rates of such
events are not known. We tested the predictions of our model for
the frequencies of such events of 0, K, and 1 and found that these
changes had no effects on the relative contributions of different cell
types to cancer initiation. INK4A/ARF, TP53, and NF1 all have
anti-proliferative effects [29,30,32] and therefore, inactivating
mutations in these genes are expected to lead to increased growth
as compared to wild type cells. Since both INK4A/ARF and TP53
are in the same pathway [31], we considered the relative fitness
of INK4A/ARF
2/2 and TP53
+/2 cells to be the same, RARF=
RTP53<1.1; this choice was made since these cells show pro-
liferation, but do not lead to a significant disruption of brain
morphology [29]. However, the relative fitness values of TP53 and
INK4A/ARF need not be equal, and we tested for cases in which
these choices vary. These values were tested over a range to
establish the robustness of the predictions. Loss of NF1, in contrast,
leads to a decreased fitness when inactivated without any
cooperating genetic alterations, but to increased fitness in
conjunction with INK4A/ARF or TP53 loss [33]. This effect was
addressed in the model by considering two fitness values – one
denoting the fitness of NF1
2/2 cells, RNF1,wt<0.05, and one





2/2 cells, RNF1,mut<1.1. Fitness and proliferation effects of
INK4A/ARF loss or TP53 mutation in an NF1
2/2 cell are
independent and so have a combined effect in double mutants;
however, INK4A/ARF loss in combination with TP53 mutation
leads to no additional effects, as the same pathway is targeted by
both alterations [31].
The number of symmetric divisions that glial TA cells can
undergo before terminally differentiating is unknown. Therefore,
we used data obtained for a different lineage of glial cells: O-2A
progenitor cells. These cells were analyzed for the existence of a
critical number of mitotic divisions before differentiating into non-
dividing oligodendrocytes; using in vitro time lapse data coupled
with a mathematical model, these cells were shown to require no
more than two divisions before obtaining competence for
differentiation [42]. After competence was achieved, we used an
average of one additional division instead of using the branching
process in Boucher et al. [42] to save on computation time. Thus
we set z<3, but also tested z=1 and larger values. Additional
proliferation of TA cells carrying INK4A/ARF, TP53, and NF1
alterations was modeled as a fixed number of additional cell
divisions bARF=bTP53 and bNF1, respectively, and initially, we set
all three equal to 1. We considered only one additional division
since there is no significant disruption of brain morphology in mice
carrying those alterations, and so little gain in cell counts is
expected [29]. In vitro, addition of PDGF to the medium results in
immortalization and de-differentiation of oligodendrocyte progen-
itor cells and astrocytes [16]; similar effects were observed in cells
with INK4A/ARF loss [43]. However, in vivo this effect has only
been demonstrated in PDGF-overexpressing cells [19]. Thus, the
potential for acquisition of self-renewing properties is most
effectively conferred by overexpression of PDGF; we further
assumed that the probability of a gamma event due to INK4A/ARF
loss is small enough to be neglected. Since there are no estimates
available for the rate at which gamma events occur, we tested a
range of values. Similarly, as there may be margins of error on any
estimate, we tested a wide range of potential values of all
parameters around the estimates obtained from the literature and
investigated the robustness of our predictions.
In response to PDGF overexpression, a 2-4-fold increase in the
size of the SVZ is observed [44]; therefore, the expansion factor
due to PDGF overexpression in the model is set to C<3. The rate
of cell division also increases about three-fold when PDGF is
overexpressed [34], leading to an increase in the number of
divisions per time step by a factor of C in our model. Somatic
mutation rates in glial cell lineages have not been measured;
instead, we used data from lymphoid cell assays as we expected
that the mutation rate in the brain is similar. The spontaneous
mutation rate per cell division per allele is approximately 0.5–
3.5610
27 [45,46]. Thus, the mutation rate per allele per cell
division of all genes was considered to be about mPDGF=
mARF=mTP53=mNF1=1.0610
27.
When comparing the relative importance of the three
populations (SR, TA, and SRTA cells) for cancer initiation, we
found that the probability of cancer initiation from SRTA cells
dominates the dynamics in the PDGF-induced case for almost all
parameter choices (Figs. 3 and S3), while in the NF1-driven case,
only SR cells can lead to cancer initiation (Fig. S4) if there is no
appreciable gamma effect associated with either NF1 or TP53 loss.
No such effect has been demonstrated for either of these alterations.
However, loss of NF1 was shown to transiently, but not
permanently, promote self-renewal [14]. This effect may contribute
to the recent finding that in a mouse model, NF1/TP53 deleted
gliomas appeared to arise fromnon-stem cells [13]. In the context of
our mathematical model, the differences between the respective
animal studies [12,13] can be accounted for by the differential
ability of NF1 and/or TP53 to induce a (short-lived) gamma effect
in cellssuchthat under certaincircumstances, a TA cell may be able
to serve as the cell of origin for this subtype of glioma.
For the mathematical model of PDGF-driven gliomas, we found
that using those parameter values that most accurately describe the
human brain results in the probability of cancer initiation from
SRTA cells dominating the dynamics for all times (Fig. 3A).
However, since many investigations were performed in the
developing brain of rodents, there may be significant variation
in parameter values when considering the human brain due to
both interspecies differences and variability between developing
and adult brain tissues. Thus, we performed a systematic analysis
of the parameter space. We defined an interval around the
estimates obtained from the literature that spans the likely values
of each parameter (Table 1) and randomly chose sets of
parameters from those intervals and examined the probability of
cancer initiation from the various cell types. The mean probability
for each cell type in PDGF-driven glioma along with the standard
error is shown in Fig. 3B. Again, the probability of cancer
initiation from SRTA cells is dominant in this analysis, followed by
the probability of cancer initiation from SR cells. We repeated
these tests for the NF1-driven case and again found that only SR
cells can initiate tumorigenesis in this scenario (Fig. 3C and 3D)i f
no gamma effect is included for this case. As gamma increases
from zero to small values, non-self-renewing cells can similarly
The Probable Cell of Origin of Glioblastomas
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perturbed each parameter individually to study the robustness of
the system to parameter variations, and found that only when the
probability of de-differentiation and immortalization remains
below 2 to 5610
25, an SR cell is the most likely cell of origin
(Fig. 3E and S3).
Figure 3. The most likely cell of origin of gliomas. A) Time course of the probability of PDGF-driven cancer initiation from SR cells (red), TA cells
(blue), SRTA cells (green), and the total probability (black) for parameter values most accurately describing the human system. Parameter values are
a=0.2, b=1, C=3, c=0.005, d=0.005 cstep=0.0005, mPDGF=10
27, mARF=10
27, N=5, RARF=1.1, and z=3. B) The most likely path to PDGF-driven
cancer initiation for a comprehensive investigation of the parameter space. For each parameter value in the system, we define an interval spanning
the likely values of the parameter (Table 1), and randomly choose combinations from the intervals. For the parameters d, c, mPDGF, and mARF, values are
chosen from a log-uniform distribution while for all other parameters, values are chosen from a uniform distribution. This choice is repeated 1,000,000
times. The mean probabilities of cancer initiation from SR (red), TA (blue) and SRTA cells (green) are shown, along with the total probability (black)
and the standard error. The probability of cancer initiation from SRTA cells is the dominant evolutionary trajectory towards brain cancer. C) Time
course of the probability of NF1-driven cancer initiation from SR cells (red), TA cells (blue), and SRTA cells (green) for parameter values most
accurately describing the human system, assuming that there is no gamma effect associated with NF1 loss. Parameter values are a=0.2, bNF1=1,
bTP53=1,C=3,d=0.005, mNF1=10
27, mTP53=10
27, N=5,RTP53=1.1, RNF1,wt=0.2, RNF1,mut=1.1, and z=3.D) The most likely path to NF1-driven cancer
initiation for a comprehensive investigation of the parameter space, assuming that there is no gamma effect associated with NF1 loss. For each
parameter value in the system, we define an interval spanning the likely values of the parameter (Table 1), and randomly choose combinations from
the intervals. For the parameters d, c, mNF1, and mTP53, values are chosen from a log-uniform distribution while for all other parameters, values are
chosen from a uniform distribution. This choice is repeated 1,000,000 times. The mean probabilities of cancer initiation from SR (red), TA (blue) and
SRTA cells (green) are shown, along with the total probability (black) and the standard error. E) The probability of cancer initiation from SR cells (red),
TA cells (blue), and SRTA cells (green) with different values of the rate at which TA cells acquire self-renewal, c. F) The probability of cancer initiation
from SR cells (red), TA cells (blue), and SRTA cells (green) with different values of the parameters c and the number of cell divisions of TA cells, z.
doi:10.1371/journal.pone.0024454.g003
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experiments, the rate at which TA cells acquire the potential to
undergo symmetric self-renewing divisions, c, is the most
important determinant of the cell of origin (Fig. 3E and S3). Let
us discuss the effects of this parameter with the example of PDGF-
driven gliomas. If c is very small (i.e., for our parameter regime,
less than five in 10
5 PDGF-overexpressing TA cells acquire self-
renewing propensities per TA cell division), then a SR cell is the
most likely cell of origin. However, if c is of the order of 10
24 or
larger, then a SRTA cell is the most likely cell of origin. We then
explored the effect of the number of cell divisions TA cells can
undergo, z, as well as c on the probabilities of cancer initiation
(Fig. 3F). Similarly, a threshold exists for values of z and c that
separates the dominant cell types for cancer initiation. When z
increases, smaller values of c are sufficient to shift the dominant
cell type from SR to SRTA cells. In sum, unless c is very small, an
SRTA cell is the most likely cell of origin of PDGF-driven gliomas.
We next investigated the effects of therapeutic interventions on
the probabilities of cancer initiation. We tested eight possible
effects of treatments of PDGF-driven gliomas: (i) therapy that
lowers gamma, thereby slowing the establishment and turnover of
SRTA cells, (ii) treatments that decrease the expansion and
recruitment of cells due to PDGF overexpression, (iii) treatments
that selectively increase the death rate of mutant SR cells, (iv)
mutant TA cells, (v) mutant SRTA cells, and (vi–viii) all
combinations of increases of death rates of the three cell types.
All other parameters are either infeasible to alter by therapy (such
as mutation rates), would have little to no effect (such as relative
fitness), or would severely disrupt the normal functioning of the
brain – such as increasing the number of cells per niche or
changing the relative rates of symmetric to asymmetric cell
divisions. Treatments that lower the chance of self-renewal
properties would be equivalent to lowering the parameter c in
the model, which would decrease the probability of cancer
initiation in SRTA and TA cells (XR and XT), but not change the
risk of cancer initiation from SR cells (Fig. S2E, F, and G). A
decrease in the expansion of PDGF-overexpressing cells is
equivalent to lowering the value of C (Fig. S2C). We found that
a lower gamma, a lower C, and higher death rate of mutant SR
cells lead to noticeable decreases in the probabilities of cancer
initiation, while higher death rates of mutant TA cells have a
negligible effect. Interestingly, higher death rates of mutant SRTA
cells actually cause a significant increase in the risk of cancer
initiation (Fig. S5). This increase is due to the SRTA population
being formed of cells that are already mutated. Thus, any
treatment that kills many, but not all, of the cells in this niche
would cause increased turnover of cells and overall a faster
accumulation of mutations. This effect becomes especially
apparent with the administration of a treatment that increases
death in SR and SRTA cells. A low death rate leads to a higher
risk of cancer, since few mutations are lost by chance. As the death
rate increases, there is a decrease in the probability of cancer
initiation as more mutations are lost from the population. Once
the death rate becomes too high, if a single mutant TA cell
successfully becomes self-renewing and forms its own mutant
SRTA cell niche, the increased turnover in this compartment
allows more mutations to arise quickly and thereby enhances the
probability of cancer initiation.
By contrast, there are relatively few effects that therapy can
have on a glioma for which gamma is near zero. Since in that case,
only SR cells can serve as the cell of origin, only those parameters
that affect the SR cells cause a difference in the rate of cancer
initiation. These parameters are a, bNF1, bTP53, d, N, RNF1,wt, and
RNF1,mut. As with PDGF-driven gliomas, most of those parameters
either have little to no effect or would significantly disrupt the
brain structure if altered. The only parameter with an effect is the
death rate, d. Contrary to the PDGF case, in a scenario with
gamma near zero, increasing the death rate would increase the
probability of cancer initiation (Fig. S2D). This effect arises due to
our modeling assumption that TP53 decreases or prevents
accidental death from occurring, thereby allowing further
accumulation of mutations in cells wild type with respect to
TP53 while preventing loss of TP53 mutated cells through
accidental death.
We then turned to mouse modeling to validate the predictions
of our mathematical framework that can be feasibly tested through
biological experimentation. Note, however, that the mathematical
model predicts the dynamics of tumor initiation rather than
diagnosis and hence our predictions cannot directly be compared
to cancer incidence data.
Targeting PDGF to GFAP-expressing cells in different
locations results in glioma formation
The experimental evidence regarding the cell of origin of NF1-
driven gliomas remains controversial. In one series of experiments,
genetic and stereotactic methods indicated that gliomas formed by
combined loss of NF1 and TP53 and/or PTEN were restricted to
neural stem/progenitor cells and were not initiated from cell types
in the cortex or cerebellum [12], while in another experimental
system, similar NF1/TP53 deleted gliomas appeared to arise from
Table 1. Range of parameter values for the human brain.
PDGF-driven gliomas
ab ARF CD c0 cstep mARF mPDGF NR ARF Zt




28 2 1.0 2 1,000




26 15 1.3 5 50,000
NF1-driven gliomas
ab NF1 bTP53 D mNF1 mTP53 NR NF1,wt RNF1,mut RTP53 Zt
Lower Bound 0.1 0 0 10
24 10
28 10
28 2 0.01 1.0 1.0 2 1,000
Upper Bound 0.3 3 3 10
21 10
26 10
26 5 0.5 1.3 1.3 5 50,000
The table shows the ranges of parameter values used to calculate the most likely path to cancer initiation (see Figs. 3B and 3D) based on estimates from the literature
(see main text for details and references). Note that in this case, we assume that there is no gamma effect associated with NF1 loss. See the main text for discussion of
alternative assumptions.
doi:10.1371/journal.pone.0024454.t001
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evidence for the PDGF-driven case. Recent evidence suggests that
PDGF- and EGFR-induced gliomas may represent a distinct
biology and cell of origin from other glioma subtypes [7,8,9,11].
Furthermore, our mathematical model predicts that non-self-
renewing cell types, specifically transit-amplifying cells, are very
likely to initiate cancer in PDGF-induced gliomas. Therefore, we
compared the extreme cases of PDGF-induced gliomagenesis from
NSCs (as defined by GFAP positivity in the SVZ) versus reactive
astrocytes (GFAP expression in the cortex, induced in response to
injury by delivery of RCAS-PDGF) in order to determine if, when
engineered into the mouse brain, it is possible to initiate cancer
from a non-self renewing cell. We used the RCAS/tv-a system to
target PDGF expression to GFAP-expressing cells of the SVZ,
cortex and cerebellum. We injected Gtv-a/ink4a/arf
2/2 transgenic
mice (where the tv-a receptor is expressed on GFAP-positive cells)
with RCAS-PDGF using the stereotactic coordinates to target the
SVZ (as a positive control for GFAP-expressing CNS stem cells),
cortex and cerebellum. While these experiments did not directly
compare transit amplifiers and neural stem/progenitor cells, they
can confirm the ability of non-self renewing cells to initiate PDGF-
induced gliomas, unlike the EGFR-induced case.
Figure 4A depicts the Kaplan-Meier survival curve of mice
injected in these three different locations. We found that all mice
injected into the SVZ developed tumors. We also found that
injection of RCAS-PDGF into the cortex resulted in 91%
incidence of gliomas located in the lateral hemisphere with latency
indistinguishable from the mice injected into the SVZ. The mice
injected in the cerebellum showed 86% incidence of glioma
formation, but exhibited a longer latency (Fig. 4B).
Tumors initiated in all three locations demonstrated histological
features of high-grade gliomas (Fig. 4C), including microvascular
proliferation and in some cases extensive areas of pseudopalisading
necrosis (Fig. 4C). All tumors generated were composed of regions
with more oligo- and mixed astrocytoma histologies, with areas
that were highly positive for GFAP and others positive for Olig2
(Fig. 5). PCNA staining of these tumors showed similar
proliferation rates and was observed for tumors that arise from
the SVZ and right hemisphere, and was lower for tumors arising in
the cerebellum (Fig. 5).
In sum, the mouse modeling experiments demonstrated a nearly
100% incidence of PDGF-induced gliomas arising from GFAP-
expressing cells in all three locations in the brain, with an equal
latency between SVZ and cortex and a longer latency in the
cerebellum. These results come in direct contrast to one of the
previously published NF1 results [12], and verify that non-self
renewing cells can potentially be the cell of origin of gliomas when
a mutation conferring self-renewal, such as PDGF overexpression,
occurs. However, this is the extent in which mouse modeling can
determine the cell of origin. Mouse modeling can demonstrate
which cell types are capable of serving as the cell of origin for
tumors, but the results depend on the oncogene and experimental
Figure 4. Overexpressing PDGFB in different locations of adult Gtv-a/Ink4a-Arf
2/2 mice leads to glioma formation. A) Kaplan-Meier
survival curve of mice injected with PDGFB in different locations of Gtv-a ink4a/arf
2/2 mice demonstrated a tumorigenic advantage of the SVZ and
right hemispheres versus the cerebellum. B) Table showing the number of mice injected tumor incidence (%) and median survival. C) Represent
whole mount H&Es for corresponding groups in Kaplan-Meier survival curve in the boxes corresponding to the color of each group. Statistical analysis
was performed to compare all the groups to the cerebellar group. All the mice without obvious evidence of tumors were sacrificed at 103 days post-
injection.
doi:10.1371/journal.pone.0024454.g004
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propensity of a cell type to initiate gliomagenesis once a certain
alteration or combination of alterations is engineered into the cell.
It cannot address the relative likelihood of different cell types to
initiate tumor development in the unperturbed system. As such,
mouse modeling does not address issues of the evolutionary
dynamics of mutations leading to tumorigenesis in humans. All of
these caveats limit the conclusions that can be drawn from mouse
modeling experiments regarding the cell of origin for tumors
caused by spontaneous mutations.
Discussion
In this paper, we have described a mathematical model of brain
cancer development and determined the dominant evolutionary
path towards cancer-initiating cells in two distinct subtypes of
glioblastoma. Use of a mathematical model is necessary to
determine the likelihood of a specific cell type to serve as the
cell of origin of a tumor: while mouse modeling can show that
certain mutations, introduced at a specific time and in a specific
place, force a biological system to develop cancer, it cannot
delineate how common such an emergence of a mutation may be.
We designed our model to test how the consideration of a potential
mechanism by which a transit-amplifying (TA) cell can become
cancerous alters the likelihood of a neural stem cell (NSC) to
initiate tumorigenesis. Using our model, we found that if one of the
genetic alterations contributing to glioma formation allows a TA
cell to undergo symmetric self-renewing divisions with a
probability larger than a very low threshold, then the cell of
origin is almost certainly a TA cell that has evolved this property.
The risk of cancer initiation from a NSC, in comparison, is
negligibly low in this situation. This scenario represents the PDGF-
driven glioma subtype. In the case of gliomas induced by NF1 loss,
the most likely cell of origin is determined by whether the initiating
oncogenic events generate an appreciable gamma effect under the
experimental conditions used. Thus, our mathematical model not
only allows the prediction of the cell of origin for different glioma
subtypes, but also helps to interpret recent conflicting findings
about the origin of NF1-driven gliomas.
For our modeling purposes, we have defined the cell of origin as
the cell that acquires the last mutation necessary since it is this cell
that initiates cancer. Our mathematical modeling experiments also
indicated that the cell that accumulates the first mutation towards
glioma is almost always a NSC. This situation arises because a TA
cell is unlikely to accumulate multiple mutations before terminally
differentiating. In many cases, the cell harboring the first mutation
will not accumulate the other alterations necessary for glioma
formation; therefore, a consideration of the cell in which the last
mutation arises is more meaningful. Alternatively to the terminol-
ogy ‘‘cell of origin’’, this cell may also be referred to as a cell
permissive for tumorigenesis, while the non-tumorigenic forbearer
may be called the cell in which the first oncogenic and ultimately
initiating event arises. Both of these cells may be distinct from
‘‘tumor-propagating’’ cells, which maintain the tumor bulk [21].
The predictions of our model are robust with regard to changes in
parameters (Fig. 3B) and with regard to variations in the structure
of the model (see Supplementary Information S1 for more
discussion). However, our model is restricted to consideration of
glioblastoma subtypes in which the considered set of alterations
arises: in a different subtype, other mechanisms may provide a
greater impact on the dynamics of tumor initiation than those
considered here. Nevertheless, should similar mechanisms be
Figure 5. Histological characteristics of tumors generated in different locations of adult Gtv-a ink4a/arf
2/2 mice by overexpressing
PDGFB. Representative images of immunostaining for GFAP, Olig2 shows that these tumors compose from regions more astrocytoma and others
more oligodendroglioma histology. PCNA immunoreactivity shows similar level of positive cells in tumors generated by injecting PDGF in SVZ and
right hemisphere and lower in cerebellum. Scale bars are 100 mm for all images.
doi:10.1371/journal.pone.0024454.g005
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would still hold. As more becomes known about the effects of
genetic and epigenetic alterations driving tumorigenesis, our
modeling approach will be useful to understand the dynamics of
other systems.
When investigating the effects of therapeutic interventions on
the probabilities of cancer initiation, we found that a lower rate at
which self-renewal is acquired (gamma), a lower expansion factor
due to PDGF-overexpression (C), and a higher death rate of
mutated SR cells (d) decrease the risk of PDGF-driven glioma
initiation, while in the case of NF1-driven gliomas, changes in SR
cell characteristics (such as the fitness advantage conferred by loss
of tumor suppressors) in addition to a potential gamma effect
associated with NF1 loss can modify the chance of cancer
initiation.
Due to the inability of mouse modeling to address the
evolutionary dynamics of an unperturbed system, the predictions
of our mathematical model concerning the relative likelihoods
of each cell type to initiate tumorigenesis cannot be directly
validated. However, the experimental system provides the
possibility of partially validating the mathematical model by
testing several conclusions of the mathematical framework: for
example, we predicted that, if one of the genetic alterations driving
tumorigenesis confers stem cell properties to cells, tumors do not
necessarily have to emerge from stem cells but can arise from any
cell type undergoing cell division. This finding is in accordance
with our experimental evidence that PDGF-driven gliomas can
originate in the SVZ, cortex and cerebellum if PDGF overexpres-
sion together with INK4A/ARF loss is engineered into the murine
brain.
Assigning probabilities for specific cell types to serve as the cells
of origin is more than an academic exercise. The cell of origin for
the three major glioma subtypes may not be the same, and the
different mutations required to transform these cells may
ultimately lead to the differences in their biology. Multiple cell
types have been shown to possess the potential to give rise to
gliomas, but the properties of the genetic alterations that initiate
the cancer phenotype greatly impact the probability of one cell
type serving as cell of origin over the others. The property that
matters the most is the rate of acquiring self-renewal, a parameter
we term gamma. Gliomas driven by oncogenic mutations that
have no appreciable gamma effect must arise from a NSC. Thus,
other combinations of alterations that do not result in a gamma
effect must also arise in a NSC. By contrast, because of the
significant gamma effect associated with dysregulated PDGF
signaling, gliomas induced by PDGF can originate in nearly any
cell including NSC, TA, OPCs and reactive astrocytes. However,
mathematical modeling determines that the most likely cell of
origin of PDGF-driven gliomas due to sporadic mutation is a
transit-amplifying cell. This interdisciplinary approach of mathe-
matical and mouse modeling not only allows us to investigate the
results of introducing mutations into different cell types in vivo, but
also to determine the likelihood that individual cell types serve as




2/2 mice were used at an age ranging from 5 to
13 weeks for all experiments. Animal experiments were conducted
using protocols approved by the Institutional Animal Care and
Use Committees of Memorial Sloan-Kettering Cancer Center.
The approved protocol number is 00-11–189 (MSKCC, last
approved date is 3/15/2010).
Cell culture and transfections
DF-1 cells were purchased from ATCC. Cells were grown at
39uC according to ATCC instructions. Transfections with RCAS-
PDGFB-HA were performed using Fugene 6 transfection kit
(Roche # 11814443001) according to manufacturer’s instruction.
Intracranial injections
Injections were performed using stereotactic fixation device
(Stoelting, Wood Dale, IL). Mice used for these experiments were
adult from 5 to 13 weeks old. Mice were anaesthetized with i.p.
injections of ketamine (0.1 mg/g) and xylazine (0.02 mg/g). 1 ml
of 4610
4 transfected DF-1 cell suspension was delivered using 30-
gauge needle attached to Hamilton syringe. Locations were
determined according to the instructions in atlas [47]. Coordinates
for SVZ injections were: AP-0 mm from bregma, Lat-1,2 mm
(right of midline), and a depth-1.5 mm from the dural surface.
Right hemisphere: AP-0 mm from bregma, Lat-3.0 mm (right)
depth-1.0 mm from dural surface. Cerebellum: AP -5.5 mm from
bregma, Lat-1.5 mm (to the left), depth-1.0 mm from the dural
surface. Mice were monitored carefully and sacrificed when they
displayed symptoms of tumor development (lethargy, head tilt).
Experiments were stopped at 103
rd day.
Tissue processing
Animals used for histological analysis were sacrificed, and brains
were removed and fixed in 10% neutral buffered formalin for
72 h. Fixed tissues were then embedded in paraffin. Formalin-
fixed, paraffin-embedded specimens were serially sectioned and
slide mounted. The sections were deparaffinized in histo-clear
(Richard-Allan Scientific) and were passed through graded
alcohols before staining with H&E reagent.
Immunohistochemistry
An automated staining processing (Discovery-XT, Ventana
Medical Systems, Inc.) was used for immunohistochemical
detection. The protocols were established at the Molecular
Cytology Core Facility and at Brain Tumor Center at MSKCC.
Anti-PCNA antibodies were obtained from DAKO (# MO879),
anti-GFAP from DAKO (Z0344) and anti-Olig2 from Millipore
(AB9610), and used at 1/2000, 1/8000 and 1/250 dilutions in 2%
BSA in PBS correspondingly.
Supporting Information
Figure S1 Fit of the analytical approximation to simu-
lation results for PDGF-driven gliomas. We investigate the
fit of the analytical approximation derived for the PDGF-driven
case with the output of exact stochastic computer simulations
while varying each parameter and keeping the other values
constant. Dots represent the results of the exact stochastic
computer simulations and curves represent the results of the
analytical approximation. The black curve shows the total
probability of cancer initiation, the red curve the probability of
cancer initiation from self-renewing (SR) cells, the blue curve the
probability of cancer initiation from transit-amplifying (TA) cells,
and the green curve the probability of cancer initiation from self-
renewing transit-amplifying (SRTA) cells. The standard parameter
values are a=0.2 (probability of a symmetric SR cell division);
bARF=1 (additional number of cell divisions of INK4A/ARF
2/2
TA cells); C=3 (expansion factor due to PDGF overexpression);
d=0.005 (per cell per division accidental death rate); c=0.005
(rate of acquisition of self-renewal in the most undifferentiated
PDGF-overexpressing TA cells); csteo=0.0005 (reduction factor of
c with each cell division); mARF=mPDGF=10
24 (mutation rate per
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(i.e. growth rate) of INK4A/ARF
2/2 SR cells); z=3 (number of TA
cell divisions);, and t=4000 (time).
(TIF)
Figure S2 Fit of the analytical approximation to simu-
lation results for NF1-driven gliomas. We investigate the fit
of the analytical approximation in the PDGF-driven case with the
output of exact stochastic computer simulations while varying each
parameter and keeping the other values constant. Dots represent
the results of the exact stochastic computer simulations and curves
represent the results of the analytical approximation. The red
curve shows the probability of cancer initiation from self-renewing
(SR) cells; all other cell types are zero and so are not displayed.
Note that this latter effect arises since we assume that there is no
appreciable gamma effect associated with NF1 loss; see the main
text for discussion of alternative assumptions. The standard
parameter values are a=0.2 (probability of a symmetric SR cell
division); bNF1=bTP53=1 (additional number of cell divisions of
NF1
2/2 and TP53-dominant negative TA cells); d=0.005 (per cell
per division accidental death rate); mNF1=mTP53=10
24 (mutation
rate per allele); N=5 (number of SR cells); RNF1,wt=0.2 (relative
fitness value (i.e. growth rate) of NF1
2/2 mutant SR cells without
TP53 or INK4A/ARF mutations); RNF1,mut=1.1 (relative fitness
value (i.e. growth rate) of NF1
2/2 mutant SR cells with TP53 or
INK4A/ARF mutations); RTP53=1.1 (relative fitness value (i.e.
growth rate) of TP53 dominant negative SR cells); z=3 (number
of TA cell divisions), and t=4000 (time).
(TIF)
Figure S3 Parameter dependence of the probabilities of
cancer initiation for PDGF-driven gliomas using muta-
tion rates of human cells. We investigate the parameter
dependence of the probabilities of cancer initiation using the
differential equation systems in the PDGF-driven case by varying
each parameter while keeping the other values constant. The red
curve shows the probability of cancer initiation from self-renewing
(SR) cells, the blue curve the probability of cancer initiation from
transit-amplifying (TA) cells, and the green curve the probability of
cancer initiation from self-renewing transit-amplifying (SRTA)
cells. Parameters are kept the same as when fitting the
approximation to simulation (Fig. S1), but the default mutation
rate is decreased to mARF=mPDGF=10
27.
(TIF)
Figure S4 Parameter dependence of the probabilities of
cancer initiation for PDGF-driven gliomas when sym-
metric differentiation is introduced. We investigate the
parameter dependence of the probabilities of cancer initiation in
the NF1-driven case by varying each parameter while keeping the
other values constant. The red curve shows the probability of
cancer initiation from self-renewing (SR) cells, the blue curve the
probability of cancer initiation from transit-amplifying (TA) cells,
and the green curve the probability of cancer initiation from self-
renewing transit-amplifying (SRTA) cells. Parameters are kept the
same as when fitting the approximation to simulation (Fig. S1), but
only asymmetric differentiation (solid lines), half symmetric
differentiation steps and half asymmetric differentiation steps
(dashed lines), and all symmetric differentiation steps (dotted lines)
are displayed. These results are derived from the exact stochastic
computer simulations.
(TIF)
Figure S5 Effect of therapeutic interventions that in-
crease the death rates in SR, TA, and SRTA cells, and all
combinations thereof on PDGF-driven gliomagenesis.
We investigate the effect of treatments that selectively increase cell
death in A) SR cells, B) TA cells, C) SRTA cells, D) SR and TA
cells, E) SR and SRTA cells, and F) TA and SRTA cells. The red
curve shows the probability of cancer initiation from self-renewing
(SR) cells, the blue curve the probability of cancer initiation from
transit-amplifying (TA) cells, and the green curve the probability of
cancer initiation from self-renewing transit-amplifying (SRTA)
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